Browse 100+ evidence-based profiles with community ratings, dosage guides, and safety information.
Start ExploringPublished 17 March 2026
N-Acetyl Cysteine (NAC) is a supplemental form of the amino acid cysteine that has been used in clinical medicine for decades - primarily as a mucolytic agent and as the standard antidote for paracetamol (acetaminophen) overdose. However, over the past 15 years, a growing body of psychiatric research has revealed that NAC possesses remarkable potential for treating a range of mental health conditions. Its ability to modulate glutamate signalling, replenish the brain's master antioxidant glutathione, and reduce neuroinflammation places it at the intersection of several pathological processes now understood to underlie conditions such as OCD, depression, bipolar disorder, and addiction.
What makes NAC particularly noteworthy is that it addresses mechanisms that conventional psychiatric medications often do not target directly. SSRIs modulate serotonin, antipsychotics block dopamine receptors, and mood stabilisers alter ion channel activity - but none of these drug classes directly address glutamate dysregulation or oxidative stress, both of which are increasingly recognised as central to psychiatric pathology. This guide examines the science behind NAC's psychiatric applications, with a particular focus on OCD, and provides practical guidance for supplementation.
NAC's psychiatric effects stem from three interconnected mechanisms. Understanding these is essential for appreciating why a single compound can show benefit across such a diverse range of conditions.
This is NAC's most important psychiatric mechanism. The cystine-glutamate antiporter (system Xc-) is a membrane transport protein found on glial cells throughout the brain. It exchanges extracellular cystine (the oxidised dimer of cysteine) for intracellular glutamate in a 1:1 ratio. NAC, as a cysteine prodrug, increases cystine availability and thereby drives this antiporter, increasing extrasynaptic glutamate release from glial cells.
This extrasynaptic glutamate activates presynaptic metabotropic glutamate receptors (mGluR2/3), which act as autoreceptors to inhibit synaptic glutamate release. The net effect is a reduction in the chaotic, excessive synaptic glutamate signalling that characterises conditions like OCD, addiction, and schizophrenia. Crucially, this mechanism is distinct from simply blocking glutamate receptors - it restores the balance between synaptic and extrasynaptic glutamate tone, normalising rather than suppressing glutamatergic transmission.
NAC is the rate-limiting precursor for glutathione (GSH), the brain's most abundant endogenous antioxidant. Cysteine availability is the bottleneck in glutathione synthesis, and NAC directly addresses this by providing bioavailable cysteine. The brain is exceptionally vulnerable to oxidative stress due to its high metabolic rate, high lipid content, and relatively limited antioxidant defences. Psychiatric conditions including depression, bipolar disorder, schizophrenia, and OCD are all associated with elevated markers of oxidative stress and reduced glutathione levels. By restoring glutathione, NAC helps protect neurons, mitochondria, and synaptic machinery from oxidative damage.
Neuroinflammation is increasingly recognised as a transdiagnostic factor in psychiatric illness. NAC reduces neuroinflammation through multiple pathways: it inhibits NF-kB (a master inflammatory transcription factor), reduces pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6, and supports microglial function. A 2021 systematic review in Progress in Neuro-Psychopharmacology and Biological Psychiatry confirmed that NAC significantly reduces inflammatory biomarkers in psychiatric populations.
Obsessive-compulsive disorder is characterised by intrusive, distressing thoughts (obsessions) and repetitive behaviours or mental acts (compulsions) performed to reduce the anxiety generated by those thoughts. While traditionally understood as a serotonergic disorder - hence the first-line use of SSRIs - current neuroscience points to a more complex picture involving glutamate dysregulation in cortico-striatal-thalamic-cortical (CSTC) circuits.
Magnetic resonance spectroscopy (MRS) studies have consistently found elevated glutamate and glutamine levels in the caudate nucleus, anterior cingulate cortex, and orbitofrontal cortex of OCD patients. These are precisely the brain regions involved in the CSTC circuits responsible for habit formation, error detection, and behavioural inhibition - the circuits that malfunction in OCD. Post-mortem studies have confirmed alterations in glutamate transporter expression in OCD, and genome-wide association studies have identified glutamate-related gene variants (SLC1A1/EAAC1) as risk factors for OCD. This converging evidence establishes glutamate dysregulation as a core pathological mechanism in OCD - and explains why NAC, as a glutamate modulator, may be beneficial.
A landmark 2012 double-blind, placebo-controlled trial published in the Journal of Clinical Psychopharmacology by Afshar et al. randomised 48 treatment-resistant OCD patients (already on stable SSRI therapy) to receive either 2,400 mg/day of NAC or placebo for 12 weeks. The NAC group showed a significant reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores compared to placebo, with a full clinical response (greater than 35% Y-BOCS reduction) achieved in 52.6% of the NAC group versus 15% of the placebo group. Importantly, these were patients who had not adequately responded to SSRIs alone.
A 2016 randomised controlled trial by Paydary et al. in Journal of Clinical Pharmacy and Therapeutics replicated these findings, reporting significant Y-BOCS improvement with NAC augmentation of fluvoxamine in moderate-to-severe OCD. A 2015 study by Costa et al. in Pharmacology Biochemistry and Behavior found similar benefits in a paediatric OCD population, suggesting efficacy across age groups.
However, a 2022 multicentre trial by Ghanizadeh et al. published in European Archives of Psychiatry and Clinical Neuroscience found more modest results, with NAC producing improvement in specific OCD symptom dimensions (particularly contamination and washing) rather than across all symptom types. This suggests that NAC may be most effective for certain OCD subtypes. A 2023 meta-analysis in Journal of Clinical Medicine pooling the available RCTs concluded that NAC demonstrates a statistically significant but moderate effect as an SSRI augmentation strategy for OCD, with the strongest evidence for treatment-resistant cases.
Major depressive disorder (MDD) is associated with elevated oxidative stress, neuroinflammation, and glutamate dysregulation - all mechanisms that NAC addresses. The rationale for NAC in depression rests on the observation that a substantial proportion of depressed patients (approximately 30-50%) do not achieve adequate remission with conventional antidepressants, and that these treatment-resistant cases often show the highest levels of inflammatory biomarkers.
A 2014 double-blind RCT by Berk et al. published in BMC Medicine found that 2,000 mg/day of NAC significantly improved depressive symptoms, functioning, and quality of life compared to placebo over 12 weeks. A key finding was that the greatest benefit emerged in the final weeks of the trial, suggesting that NAC's antidepressant effects build gradually as oxidative balance and glutamate homeostasis are restored.
A 2016 systematic review and meta-analysis published in the Journal of Clinical Psychiatry by Fernandes et al. analysed five RCTs and found a statistically significant improvement in depressive symptoms with NAC supplementation (SMD = -0.37, 95% CI -0.60 to -0.13), with the strongest effects observed in participants with higher baseline depression severity and those with comorbid bipolar disorder. However, more recent large-scale trials have produced mixed results, and a 2020 Cochrane-style review suggested that while NAC is promising, the evidence is not yet definitive for unipolar depression alone.
The evidence for NAC in bipolar disorder is among the most consistent in the psychiatric NAC literature. Bipolar disorder is characterised by particularly severe oxidative stress and mitochondrial dysfunction, making it a strong theoretical target for NAC.
A pivotal 2008 multicentre RCT by Berk et al. published in Biological Psychiatry randomised 75 participants with bipolar disorder to receive either 2,000 mg/day NAC or placebo as an adjunct to existing mood stabilisers for 24 weeks. The NAC group showed significant improvements in depression, mania, quality of life, and global functioning. The Montgomery-Asberg Depression Rating Scale (MADRS) scores improved by an average of 10 points more in the NAC group, a clinically meaningful difference. Subsequent open-label extension studies confirmed that these benefits were maintained with continued use.
A 2019 meta-analysis by Zheng et al. in Journal of Affective Disorders pooling bipolar studies confirmed statistically significant improvements in depressive symptoms and global functioning with NAC augmentation, though effects on manic symptoms were less consistent.
Addiction is increasingly understood as a disorder of glutamate homeostasis. Chronic substance use downregulates the cystine-glutamate antiporter, reducing extrasynaptic glutamate tone and impairing prefrontal inhibitory control over drug-seeking behaviour. NAC directly reverses this deficit. Clinical trials have shown benefit for cannabis dependence (Gray et al., 2012, American Journal of Psychiatry), nicotine cessation, gambling disorder (Grant et al., 2007, Biological Psychiatry), and cocaine craving. A 2017 systematic review in American Journal of Addictions concluded that NAC shows moderate evidence for reducing cravings and relapse across multiple addictive disorders.
These body-focused repetitive behaviours share compulsive features with OCD and respond to similar glutamate-modulating interventions. A 2009 double-blind RCT by Grant et al. published in Archives of General Psychiatry found that 1,200-2,400 mg/day of NAC was significantly more effective than placebo for reducing trichotillomania (hair-pulling) symptoms, with 56% of the NAC group rated as much or very much improved compared to 16% on placebo.
Oxidative stress and glutamate dysregulation are both prominent in schizophrenia. A 2008 RCT by Berk et al. in Biological Psychiatry found that 1,000 mg twice daily of NAC improved negative symptoms, general psychopathology, and akathisia in schizophrenia patients on stable antipsychotic therapy. A subsequent multicentre trial and a 2018 meta-analysis supported modest benefits for negative symptoms, though effects on positive symptoms are less clear.
This stack targets OCD through three distinct mechanisms. NAC modulates glutamate, magnesium provides NMDA antagonism and promotes GABA activity, and inositol (at high doses) has independent evidence for reducing OCD symptoms via serotonergic mechanisms. All three are well tolerated and can be used alongside SSRI therapy. Discuss with your prescriber before starting.
A broadly supportive stack for depressive symptoms and mood instability. Omega-3 and vitamin D both have their own evidence base for depression and complement NAC's antioxidant and anti-inflammatory mechanisms.
NAC occupies a unique position in psychiatric supplementation. Its ability to modulate glutamate signalling, restore glutathione levels, and reduce neuroinflammation addresses pathological mechanisms that conventional psychiatric medications largely do not target. The evidence is strongest for OCD augmentation, bipolar depression, trichotillomania, and addiction - conditions that share underlying glutamate dysregulation. For depression, the evidence is promising but less conclusive.
If you are considering NAC for mental health support, the most important principles are: use it as an adjunct to (not a replacement for) professional treatment, allow 8-12 weeks for effects to develop, and use evidence-based dosages of 2,000-2,400 mg per day. For a full profile of NAC including its broader nootropic effects, see our NAC profile page. For general information on nootropics and anxiety, our anxiety guide provides broader context.
NAC has clinical evidence supporting its use as an adjunctive treatment for OCD, depression, bipolar disorder, addiction, and schizophrenia. The strongest evidence is for OCD and addictive behaviours, where NAC's modulation of glutamate signalling appears to reduce compulsive urges. It also shows promise for depression through its antioxidant and anti-inflammatory effects. NAC should be used alongside - not instead of - professional treatment for any psychiatric condition.
Most clinical trials have used 1,000 to 2,400 mg of NAC daily for mental health applications, typically split into two doses (morning and evening). A common approach is starting at 600 mg twice daily and increasing to 1,200 mg twice daily if well tolerated. Benefits usually develop over 8 to 12 weeks of consistent use. Always take NAC with food to minimise digestive discomfort.
NAC works through three main mechanisms in the brain. First, it is the rate-limiting precursor to glutathione, the brain's primary antioxidant, reducing oxidative stress that contributes to psychiatric symptoms. Second, it modulates glutamate signalling through the cystine-glutamate antiporter, restoring balance to the brain's main excitatory neurotransmitter system. Third, it has anti-inflammatory effects that reduce neuroinflammation, which is increasingly linked to depression, OCD, and other conditions.
NAC is generally considered safe to take alongside most antidepressants, and many clinical trials have specifically studied it as an adjunctive treatment alongside SSRIs and other psychiatric medications. Unlike St. John's Wort or 5-HTP, NAC does not directly affect serotonin levels, so serotonin syndrome is not a concern. However, you should always inform your prescribing doctor before adding NAC or any supplement to your medication regimen.
NAC typically requires 8 to 12 weeks of consistent daily use before meaningful improvements are observed in OCD or depression symptoms. Some people notice subtle changes in mood or reduced compulsive urges within the first few weeks, but full therapeutic benefits develop over 2 to 3 months. Clinical trials showing significant results have generally lasted 12 to 24 weeks, so patience and consistency are essential.